細胞・遺伝子治療開発製造受託機関（CDMO）の世界市場レポート 2025年

細胞・遺伝子治療開発製造受託機関（CDMO）市場規模は、今後数年で飛躍的な成長が見込まれます。2029年にはCAGR27.8％で185億4,000万米ドルに成長します。予測期間の成長は、治療用途の拡大、規制の進化、投資の増加、技術革新、世界の協力関係などに起因すると考えられます。予測期間における主な動向としては、個別化治療に対する需要の増加、自動化とデジタル化の進展、製造能力の拡大、新規送達システムの出現、持続可能性と環境への影響への注目の高まりなどが挙げられます。

がん患者の増加は、細胞・遺伝子治療開発製造受託機関（CDMO）市場の成長を促進すると予想されます。異常細胞の制御不能な増殖と拡散を特徴とするがんは、人口の高齢化、ライフスタイルの変化、環境暴露、検出方法の改善により、より一般的になりつつあります。CDMOは、有効性と患者の転帰を改善する革新的な標的治療を開発・製造することで、がんと闘う上で重要な役割を果たしています。例えば、英国を拠点とする慈善団体マクミラン・キャンサー・サポートによると、英国でがんと共に生きる人の数は、2022年の300万人から2025年には350万人、2030年には400万人、2040年には530万人に増加すると予測されています。その結果、がん患者の増加が細胞・遺伝子治療CDMO市場の成長を後押ししています。

細胞・遺伝子治療開発製造受託機関（CDMO）市場の主要企業は、細胞ベースの製品製造のスケーラビリティ、効率性、品質を向上させるために、PluriMatrix技術などの先進的なソリューションを統合することで、ポートフォリオの拡大に注力しています。PluriMatrixテクノロジーは、細胞ベースの製品の大規模生産のために設計された独自のシステムです。この革新的な技術は、工業的規模での細胞の3次元増殖を可能にし、自動化され、完全に制御され、検証されたプロセスを通じて、高い収率と一貫した品質を保証します。例えば、2024年1月、イスラエルに本社を置くバイオテクノロジー企業Pluriは、CDMOとして細胞治療製造サービスを提供する新事業部門PluriCDMOを導入しました。この新事業部には、47,000平方フィートのGMP（医薬品製造管理及び品質管理基準）準拠の細胞治療製造施設があります。プルリ社が新たに設立した事業部は、前臨床の初期段階から後期臨床試験、商業化に至るまで、エンド・ツー・エンドのサービスを提供し、プロセスおよび分析開発、スケールアップ、バリデーション、ロジスティクス、自動化、規制当局が承認した比較可能性試験などをカバーする、と同社は発表しています。同社は、最先端のPluriMatrix技術を活用し、高度な細胞治療製造サービスを提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界細胞・遺伝子治療開発製造受託機関（CDMO） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の細胞・遺伝子治療開発製造受託機関（CDMO）市場：成長率分析
• 世界の細胞・遺伝子治療開発製造受託機関（CDMO）市場の実績：規模と成長, 2019-2024
• 世界の細胞・遺伝子治療開発製造受託機関（CDMO）市場の予測：規模と成長, 2024-2029, 2034F
• 世界細胞・遺伝子治療開発製造受託機関（CDMO）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の細胞・遺伝子治療開発製造受託機関（CDMO）市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子治療
• 遺伝子組み換え細胞療法
• 細胞療法
• 世界の細胞・遺伝子治療開発製造受託機関（CDMO）市場フェーズ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェーズ1
• フェーズ2
• フェーズ3
• フェーズ4
• 世界の細胞・遺伝子治療開発製造受託機関（CDMO）市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 感染症
• 神経疾患
• 希少疾患
• その他の適応症
• 世界の細胞・遺伝子治療開発製造受託機関（CDMO）市場遺伝子治療の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ウイルスベクターを用いた遺伝子治療
• 非ウイルス遺伝子治療
• プラスミドDNAを用いた遺伝子治療
• 世界の細胞・遺伝子治療開発製造受託機関（CDMO）市場遺伝子改変細胞療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• CAR-T細胞療法
• TCR-T細胞療法
• NK細胞療法
• 世界の細胞・遺伝子治療開発製造受託機関（CDMO）市場細胞療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 幹細胞療法
• 前駆細胞療法
• 免疫細胞療法

第7章 地域別・国別分析

• 世界の細胞・遺伝子治療開発製造受託機関（CDMO）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の細胞・遺伝子治療開発製造受託機関（CDMO）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 細胞・遺伝子治療開発製造受託機関（CDMO）市場：競合情勢
• 細胞・遺伝子治療開発製造受託機関（CDMO）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • FUJIFILM Diosynth Biotechnologies Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AGC Biologics
• Ajinomoto Co Inc.
• Lonza Group
• Catalent Inc.
• Charles River Laboratories International Inc.
• Sartorius Stedim Biotech
• Samsung Biologics Co Ltd
• WuXi Biologics
• Recipharm AB
• Almac Group Ltd
• KBI Biopharma
• Rentschler Biopharma
• Bio Elpida
• Oxford BioMedica Plc
• Avid Bioservices Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 細胞・遺伝子治療開発製造受託機関（CDMO）市場2029：新たな機会を提供する国
• 細胞・遺伝子治療開発製造受託機関（CDMO）市場2029：新たな機会を提供するセグメント
• 細胞・遺伝子治療開発製造受託機関（CDMO）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A cell and gene therapy contract development and manufacturing organization (CDMO) is a specialized company that supports the development, manufacturing, and commercialization of cell-based and gene therapy products. These organizations provide services tailored to the specific needs of companies developing advanced therapies, including biopharmaceutical companies, academic institutions, and government agencies. Cell and gene therapy CDMOs are crucial in speeding up the development and commercialization of advanced therapy products by offering specialized expertise, infrastructure, and services from early-stage development through to commercialization.

The primary product types offered by cell and gene therapy contract development and manufacturing organizations (CDMOs) include gene therapy, gene-modified cell therapy, and cell therapy. Gene therapy involves altering or manipulating the genes within a person's cells to treat or prevent disease. These therapies undergo various phases, including phase 1, phase 2, phase 3, and phase 4, and are developed for a range of indications such as oncology, infectious diseases, neurological disorders, rare diseases, and others.

The cell and gene therapy contract development and manufacturing organization (CDMO) market research report is one of a series of new reports from The Business Research Company that provides cell and gene therapy contract development and manufacturing organization (CDMO) market statistics, including cell and gene therapy contract development and manufacturing organization (CDMO) industry global market size, regional shares, competitors with a cell and gene therapy contract development and manufacturing organization (CDMO) market share, detailed cell and gene therapy contract development and manufacturing organization (CDMO) market segments, market trends, and opportunities, and any further data you may need to thrive in the cell and gene therapy contract development and manufacturing organization (CDMO) industry. This cell and gene therapy contract development and manufacturing organization (CDMO) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell and gene therapy contract development and manufacturing organization (CDMO) market size has grown exponentially in recent years. It will grow from $5.41 billion in 2024 to $6.94 billion in 2025 at a compound annual growth rate (CAGR) of 28.2%. The growth in the historic period can be attributed to increased technological advancements, favorable regulatory frameworks, increased investment, high prevalence of genetic disorders, and an increased number of strategic partnerships.

The cell and gene therapy contract development and manufacturing organization (CDMO) market size is expected to see exponential growth in the next few years. It will grow to $18.54 billion in 2029 at a compound annual growth rate (CAGR) of 27.8%. The growth in the forecast period can be attributed to expanded therapeutic applications, regulatory evolution, increased investment, technological innovations, and global collaboration. Major trends in the forecast period include increased demand for personalized therapies, growth in automation and digitalization, expansion of manufacturing capacities, emergence of novel delivery systems, and heightened focus on sustainability and environmental impact.

The increasing prevalence of cancer cases is expected to drive the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Cancer, characterized by uncontrolled growth and spread of abnormal cells, is becoming more common due to aging populations, lifestyle changes, environmental exposures, and improved detection methods. CDMOs play a crucial role in combating cancer by developing and manufacturing innovative, targeted treatments that improve efficacy and patient outcomes. For example, according to Macmillan Cancer Support, a UK-based charitable organization, the number of people living with cancer in the UK is projected to rise from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the increasing prevalence of cancer cases is fueling the growth of the cell and gene therapy CDMO market.

Major companies in the cell and gene therapy contract development and manufacturing organization (CDMO) market are concentrating on broadening their portfolio by integrating advanced solutions such as PluriMatrix technology to improve the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary system designed for large-scale production of cell-based products. This innovative technology enables 3D expansion of cells on an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For example, in January 2024, Pluri, a biotech company based in Israel, introduced PluriCDMO, a new business division providing cell therapy manufacturing services as a CDMO. This new division encompasses a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri's newly established division delivers end-to-end services ranging from early preclinical stages to late-stage clinical trials and commercialization, covering process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as outlined in a company announcement. It harnesses the company's state-of-the-art PluriMatrix technology to provide advanced cell therapy manufacturing services.

In November 2023, Ajinomoto Co. Inc., a Japan-based company specializing in food and biotechnology, purchased Forge Biologics for $620 million. This acquisition enhances Ajinomoto's worldwide expertise in adeno-associated virus (AAV) and plasmid gene therapy manufacturing, strengthening its current contract development and manufacturing services. Forge Biologics, based in the US, is a contract development and manufacturing organization (CDMO) for gene therapy and a clinical-stage therapeutics company.

Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc, Merck & Co. Inc., Thermo Fisher Scientific Inc, Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc, Lonza Group, Catalent Inc, Charles River Laboratories International Inc, Sartorius Stedim Biotech, Samsung Biologics Co Ltd, WuXi Biologics, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc, Cell and Gene Therapy Catapult, VGXI Inc, Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cell and gene therapy contract development and manufacturing organization (CDMO) market includes revenues earned by contract development and manufacturing organizations providing services for the development, manufacturing, and testing of cell and gene therapy products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell and gene therapy contract development and manufacturing organization (cdmo) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cell and gene therapy contract development and manufacturing organization (cdmo) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cell and gene therapy contract development and manufacturing organization (cdmo) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Gene Therapy; Gene-Modified Cell Therapy; Cell Therapy
• 2) By Phase: Phase 1; Phase 2; Phase 3; Phase 4
• 3) By Indication: Oncology; Infectious Diseases; Neurological Disorders; Rare Diseases; Other Indications
• Subsegments:
• 1) By Gene Therapy: Viral Vector-Based Gene Therapy; Non-Viral Gene Therapy; Plasmid DNA-Based Gene Therapy
• 2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy; TCR-T Cell Therapy; NK Cell Therapy
• 3) By Cell Therapy: Stem Cell Therapy; Progenitor Cell Therapy; Immune Cell Therapy
• Companies Mentioned: Pfizer Inc; Merck & Co. Inc.; Thermo Fisher Scientific Inc; Novartis AG; FUJIFILM Diosynth Biotechnologies
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Characteristics

3. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Trends And Strategies

4. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Growth Rate Analysis
• 5.4. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Total Addressable Market (TAM)

6. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Segmentation

• 6.1. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Therapy
• Gene-Modified Cell Therapy
• Cell Therapy
• 6.2. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phase 1
• Phase 2
• Phase 3
• Phase 4
• 6.3. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Infectious Diseases
• Neurological Disorders
• Rare Diseases
• Other Indications
• 6.4. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Viral Vector-Based Gene Therapy
• Non-Viral Gene Therapy
• Plasmid DNA-Based Gene Therapy
• 6.5. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Sub-Segmentation Of Gene-Modified Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CAR-T Cell Therapy
• TCR-T Cell Therapy
• NK Cell Therapy
• 6.6. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Sub-Segmentation Of Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stem Cell Therapy
• Progenitor Cell Therapy
• Immune Cell Therapy

7. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Regional And Country Analysis

• 7.1. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 8.1. Asia-Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 9.1. China Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview
• 9.2. China Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 10.1. India Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 11.1. Japan Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview
• 11.2. Japan Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 12.1. Australia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 13.1. Indonesia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 14.1. South Korea Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview
• 14.2. South Korea Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 15.1. Western Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview
• 15.2. Western Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 16.1. UK Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 17.1. Germany Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 18.1. France Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 19.1. Italy Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 20.1. Spain Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 21.1. Eastern Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview
• 21.2. Eastern Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 22.1. Russia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 23.1. North America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview
• 23.2. North America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 24.1. USA Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview
• 24.2. USA Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 25.1. Canada Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview
• 25.2. Canada Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 26.1. South America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview
• 26.2. South America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 27.1. Brazil Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 28.1. Middle East Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview
• 28.2. Middle East Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

• 29.1. Africa Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview
• 29.2. Africa Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Competitive Landscape And Company Profiles

• 30.1. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Competitive Landscape
• 30.2. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. FUJIFILM Diosynth Biotechnologies Overview, Products and Services, Strategy and Financial Analysis

31. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Other Major And Innovative Companies

• 31.1. AGC Biologics
• 31.2. Ajinomoto Co Inc.
• 31.3. Lonza Group
• 31.4. Catalent Inc.
• 31.5. Charles River Laboratories International Inc.
• 31.6. Sartorius Stedim Biotech
• 31.7. Samsung Biologics Co Ltd
• 31.8. WuXi Biologics
• 31.9. Recipharm AB
• 31.10. Almac Group Ltd
• 31.11. KBI Biopharma
• 31.12. Rentschler Biopharma
• 31.13. Bio Elpida
• 31.14. Oxford BioMedica Plc
• 31.15. Avid Bioservices Inc.

32. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

34. Recent Developments In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

35. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market High Potential Countries, Segments and Strategies

• 35.1 Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer